This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: An Irrational Stock Market

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- There are exceptions to every rule, Jim Cramer told his "Mad Money" TV show viewers Wednesday. When it comes to the stock market, everything is most definitely not rational.

Cramer said the industrial stocks continue to soar despite having nothing new to say. Meanwhile, Johnson & Johnson (JNJ) saw its shares barely dinged despite cutting estimates.

In the tech sector, investors continue to pile into stocks like (AMZN) and LinkedIn (LNKD), two stocks that don't seem to be constrained by traditional metrics, said Cramer.

And then there's Apple (AAPL), a stock Cramer owns for his charitable trust, Action Alerts PLUS . Apple's in-line results were seen as a disappointment, said Cramer, sending its shares down 8% in after-hours trading.

Despite having $137 billion in cash and pretty good earnings, the markets were focused on gross margins, which came in below consensus at 38.6%. The number of iPhones sold was also a tad below what Wall Street was expecting. Are sellers just taking profits or are they worn down by the stocks' total lack of momentum?

Cramer said it doesn't matter what the reason, but investors need to remove the emotions from Apple and realize that it's just another stock, one that will likely deliver decent, but not spectacular, earnings from here on out. Apple has a ton of potential, he said, but under Tim Cook we have yet to see any blockbuster new products that don't cannibalize existing ones.

"Don't let this one stock blind you to the other opportunities the market is offering," Cramer concluded.

Know Your IPO

In the "Know Your IPO" segment, Cramer highlighted Zoetis, the animal health division of Pfizer (PFE - Get Report), which is expected to offer 86.1 million shares next week between $22 and $25 a share.

Cramer said that Zoeits plays into the $22 billion animal health market, in which it currently has a 19% share. The new company makes everything from vaccines to feed additives and will derive 65% of its revenue from livestock and the remaining 35% from horses and household pets.

Cramer noted that unlike the human health-care market, most animal patient bills are paid out of pocket. When it comes to drugs and vaccines, there is far less generic competition. Given the stock's expected valuation and growth rate of 6%, Cramer said he expects Zoetis to have 20% upside from its IPO.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DD $72.78 1.60%
GOOG $552.05 0.68%
IBM $162.92 1.60%
PFE $34.96 1.20%
TRV $109.44 2.20%


DOW 17,989.89 +277.23 1.57%
S&P 500 2,085.06 +24.04 1.17%
NASDAQ 4,939.4490 +48.23 0.99%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs